Treatment of severe hypertension with Catapres (St 155). A comparative study of the effect of catapres and methyldopa in a series of hypertensive outpatients (WHO stage 3).
D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents; D001794:Blood Pressure / Q000187:drug effects; D002752:Chlorthalidone / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D004573:Electrolytes / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate; D006413:Hematopoietic System / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007668:Kidney / Q000187:drug effects; D008099:Liver / Q000187:drug effects; D008297:Male; D008750:Methyldopa / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D011187:Posture; D012160:Retina / Q000187:drug effects
D000959:Antihypertensive Agents; D004573:Electrolytes; D007093:Imidazoles; D008750:Methyldopa; D003404:Creatinine; D002752:Chlorthalidone